Alzheon presents positive results of ALZ-801 clinical studies
Pharmacokinetic and safety data from Phase Ib studies with ALZ-801, an optimized prodrug of tramiprosate, presented at the Alzheimer's Association International Conference.
Alzheon has announced the results from two Phase Ib studies of ALZ-801, which provide the final clinical data necessary to progress ALZ-801 into the pivotal Phase III program in Alzheimer’s disease (AD) patients who are homozygous for the ε4 allele of the apolipoprotein E gene (APOE4/4). ALZ-801 is an optimized prodrug of tramiprosate, the active agent in ALZ-801, and clinical development of ALZ-801 builds on the established safety and efficacy profile of tramiprosate from two prior Phase III trials in more than 2,000 AD patients.
The Phase Ib study results demonstrated favourable gastrointestinal tolerability, consistent and sustained plasma levels, and allowed selection of an ALZ-801 clinical dose that is bioequivalent to the tramiprosate dose that showed promising efficacy in prior Phase III trials. These data are being presented for the first time at the Alzheimer’s Association International Conference (AAIC), held 24–28 July in Toronto, Canada. Alzheon is also making a late-breaking presentation with new analyses of the prior tramiprosate Phase III studies that include: 1) pooled safety analyses from 2,025 subjects across the two studies, 2) centralized assessment of brain MRI for occurrence of vasogenic edema or amyloid-related imaging abnormalities (ARIA), and 3) efficacy analyses in the apolipoprotein E4 (APOE4) subgroups, suggesting promising efficacy and favorable safety profile in Mild and Moderate AD patients with the APOE4/4 genotype.
“We now have all of the necessary clinical, toxicology and tablet data to start the pivotal Phase 3 program with ALZ-801, an oral, amyloid-targeting drug candidate for the treatment of patients with Mild to Moderate Alzheimer’s disease,” said Martin Tolar, Founder, President and CEO of Alzheon. “Our body of ALZ-801 data and analyses suggest a well-differentiated and potentially transformative Alzheimer’s medicine: an oral tablet that targets the underlying amyloid pathology in Alzheimer’s, with compelling clinical efficacy in patients who are apolipoprotein E4 carriers. For the first approval for ALZ-801, we are preparing to initiate the ALZ-801 Phase III registration program in early 2017, focusing on the APOE4/4 homozygous patients that showed the most robust efficacy and represent a genetically-defined population with high unmet medical need.”
Alzheon conducted the two Phase Ib clinical studies of ALZ-801 in healthy elderly volunteers: a single dose tablet bioequivalence study, and a multiple-ascending dose safety, tolerability and pharmacokinetic study. These studies showed that ALZ-801 demonstrates favourable pharmacokinetic (PK) properties, including steady target plasma levels with low inter-subject variability, as well as sustained plasma concentrations up to 24 hours. ALZ-801 showed an equivalent or improved PK profile compared to tramiprosate, including plasma exposures and dose proportionality, thereby allowing bioequivalence and bridging to the prior clinical data with tramiprosate. ALZ-801 also showed a favourable safety and tolerability profile, including improved gastrointestinal tolerability with lower incidence of nausea and vomiting compared to previous studies with tramiprosate.
“We are extremely pleased with these clinical results for ALZ‐801, which show that we have successfully optimized the pharmaceutical, pharmacokinetic and tolerability profile so that ALZ-801 is well positioned to advance into Phase III pivotal studies, and to potentially offer an important advance in AD treatment. In addition, we are excited to show that we have developed a simple, yet superior immediate-release tablet dose that can be used in the Phase III program and subsequently in broad commercial development,” said John Hey, Chief Scientific Officer of Alzheon.
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance